JANX — Janux Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.84bn
- $810.04m
- $10.59m
- 51
- 20
- 20
- 21
Annual income statement for Janux Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.64 | 8.61 | 8.08 | 10.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 4.84 | 36.6 | 75.7 | 81.1 | 109 |
| Operating Profit | -4.84 | -32.9 | -67.1 | -73 | -98.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -6.78 | -32.7 | -63.1 | -58.3 | -69 |
| Net Income After Taxes | -6.78 | -32.7 | -63.1 | -58.3 | -69 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.78 | -32.7 | -63.1 | -58.3 | -69 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.78 | -32.7 | -63.1 | -58.3 | -69 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.17 | -0.785 | -1.52 | -1.32 | -1.28 |
| Dividends per Share |